Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
Open accessAbstract
AIMS: To determine prospectively the efficacy, tolerability and patient satisfaction of an extended release formulation of metformin (metformin XR) in hospital based outpatients with type 2 diabetes mellitus currently treated with standard metformin. METHODS: Patients on immediate release standard metformin either alone or combined with other oral agents were switched to extended release metformin XR 500 mg tablets and titrated to a maximum dose of 2000 mg/day Measurements to include glucose and lipid control, blood pressure, body weight, waist circumference, C-reactive protein, adverse events and patient satisfaction were recorded at baseline, three and six months. RESULTS: Complete data were obtained for 35 of the 61 patients enrolled to the study. At three and six months no changes were reported for any of the cardiovascular risk factors except for lipids where there was a modest rise in plasma triglycerides. These effects were achieved with a reduced dose of metformin XR compared to pre-study dosing with standard metformin (1500 mg +/- 402 vs 1861 +/- 711 p = 0.004). A total of 77% of patients were free of gastrointestinal side effects and 83% of patients stated a preference for metformin XR at the end of the study. Ghost tablets were reported in the faeces by the majority of the patients (54.1%). CONCLUSIONS: Patients switched to extended release metformin XR derived the same clinical and metabolic benefits as for standard metformin but with reduced dosage, fewer gastrointestinal side effects and a greater sense of well being and satisfaction on medication.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a prospective open label study, no significant differences were observed in any anthropometric, clinical, or laboratory measures except plasma triglycerides, which were lower in the group switched to metformin XR.
“No significant differences were observed by any anthropometric, clinical, or laboratory measures except for plasma triglycerides which were lower in the group switched to metformin XR [181].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [181]
Metformin tolerability as well as patient acceptance was greater in the group switched to metformin XR.
“Metformin tolerability as well as patient acceptance was greater in the group switched to metformin XR.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297 · see citing works
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · see citing works
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,672 · see citing works
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,489 · cited 1× · see citing works
“Lifestyle change and the use of pharmaceutical therapies are considered pivotal to achieving good control of glycaemia and other cardiovascular risk factors in the expectation of avoiding long-term complications and premature mortality [9].”
BackgroundBailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726 · see citing works
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,638 · see citing works
Standards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. S. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,414 · see citing works
Impaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396 · see citing works
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377 · see citing works
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203 · see citing works
International Diabetes Federation: a consensus on Type 2 diabetes prevention
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02157.x · Cited by 778 · see citing works
Efficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519 · see citing works
Donnan, P. T., MacDonald, T. M., & Morris, A. D. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00689.x · Cited by 435 · see citing works
Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care
IDF Clinical Guidelines Task Force (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01918.x · Cited by 433 · see citing works
The Diabetes Prevention Program Research Group (2005) · Diabetes · doi:10.2337/diabetes.54.5.1566 · Cited by 333 · see citing works
Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin
Ting, R. Z.-W. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.18.1975 · Cited by 333 · see citing works
Wu, J. Y. F., Leung, W. Y. S., Chang, S., Lee, B., Zee, B. C.-Y., Tong, P. C. Y., & Chan, J. C. N. (2006) · BMJ · doi:10.1136/bmj.38905.447118.2f · Cited by 220 · see citing works
Blonde, L., DAILEY, G. E., Jabbour, S. A., Reasner, C. A., & Mills, D. J. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003278 · Cited by 153 · see citing works
Caballero, A. E., Delgado, A., Aguilar-Salinas, C. A., Herrera, A. N., Castillo, J. L., Cabrera, T., Gomez-Perez, F. J., & Rull, J. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0019 · Cited by 151 · see citing works
Steady-State Pharmacokinetics of a Novel Extended-Release Metformin Formulation
Timmins, P., Donahue, S., Meeker, J. B., & Marathe, P. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544070-00004 · Cited by 120 · see citing works
Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., & Ridker, P. M. (2009) · JAMA · doi:10.1001/jama.2009.1347 · Cited by 117 · see citing works
Donnelly, L. A., Morris, A. D., & Pearson, E. R. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00973.x · Cited by 78 · see citing works
Fujioka, K., Brazg, R. L., Raz, I., Bruce, S., Joyal, S., Swanink, R., & Pans, M. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00369.x · Cited by 73 · see citing works
Fujioka, K., Pans, M., & Joyal, S. V. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80093-0 · Cited by 64 · see citing works
Gomes, M. B., Gianella, D., Faria, M. D. S., Tambascia, M. A., Fonseca, R. M., Rea, R. R., Macedo, G., Filho, J. M., Schmid, H., Bittencourt, A. V., et al. (2006) · The Review of Diabetic Studies · doi:10.1900/rds.2006.3.82 · Cited by 60 · see citing works
Self-citationMetformin - The gold standard:a scientific handbook
Bailey, C. J., Campbell, I. W., Chan, J. C. N., Davidson, J. A., Howlett, H. C. S., & Ritz, P. (2007) · Cited by 51 · see citing works
Scarpello, J. H. B. (2001) · The British Journal of Diabetes · doi:10.1177/14746514010010010501 · Cited by 45 · see citing works
New prolonged-release metformin improves gastrointestinal tolerability
Davidson, J. A., & Howlett, H. C. S. (2004) · The British Journal of Diabetes · doi:10.1177/14746514040040041101 · Cited by 40 · see citing works
Feher, M. D., Al‐Mrayat, M., Brake, J., & Leong, K. S. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070050501 · Cited by 33 · see citing works
Menzies, D. G., Campbell, I. W., McBain, A. M., & Brown, I. R. F. (1989) · Current Medical Research and Opinion · doi:10.1185/03007998909115209 · Cited by 18 · see citing works
Effect of plasma metformin concentrations on serum lipid levels in type II diabetic patients
Marchetti, P., Benzi, L., Cerri, M., Cecchetti, P., GIANNARELLI, R., Giannecchini, M., Cianni, G. D., Cristofani, R., Miccoli, R., Bertolotto, A., et al. (1988) · Acta Diabetologica · doi:10.1007/bf02581246 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399 · see citing works
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373 · see citing works
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567 · see citing works
Self-citationPharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L. L., Booth, G. L., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. H. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 247 · see citing works
Metformin: New Preparations and Nonglycemic Benefits
Fujita, Y., & Inagaki, N. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0829-8 · Cited by 91 · see citing works
Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus
Jabbour, S. A., & Ziring, B. S. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2241 · Cited by 82 · see citing works
Overview of metformin: special focus on metformin extended release
Ali, S., & Fonseca, V. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.705829 · Cited by 66 · see citing works
Hauber, B., Yang, Tunceli, González, J. M., Brodovicz, K. G., Zhang, Q., Han, Gantz, Alexander, C. M., Davies, et al. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s43465 · Cited by 50 · see citing works
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
Blonde, L., Dipp, S., & Cadena, D. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0694-0 · Cited by 45 · see citing works
Aggarwal, N., Singla, A., Mathieu, C., Montanya, E., Pfeiffer, A. F. H., JOHNSSON, E. K., Zhao, J., Iqbal, N., & Bailey, C. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13104 · Cited by 38 · see citing works
Shao, J., Kraft, J. C., Li, B., Yu, J., Freeling, J. P., Koehn, J., & Ho, R. J. Y. (2016) · Nanomedicine · doi:10.2217/nnm.16.1 · Cited by 34 · see citing works
Abdulkadir, A. A. A., & Thanoon, I. A. J. (2012) · Sultan Qaboos University medical journal · doi:10.12816/0003088 · Cited by 29 · see citing works
Nabrdalik, K., Hendel, M., Irlik, K., Kwiendacz, H., Łoniewski, I., Bucci, T., Alam, U., Lip, G. Y. H., Gumprecht, J., & Skonieczna‐Żydecka, K. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01727-w · Cited by 28 · see citing works
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 32 · see citing works
Evolving Metformin Treatment Strategies in Type-2 Diabetes
Chacra, A. R. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f1bb · Cited by 18 · see citing works
Pharmacologic Weight Management in the Era of Adolescent Obesity
Raman, V. S., Gupta, A., Ashraf, A. P., Breidbart, E., Gourgari, E., Kamboj, M. K., Kohn, B., Krishnan, S., Lahoti, A., Matlock, K. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac418 · Cited by 15 · see citing works
Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15 · see citing works
What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment
Romualdi, D., Versace, V., & Lanzone, A. (2020) · Therapeutic Advances in Reproductive Health · doi:10.1177/2633494120908709 · Cited by 17 · see citing works
Metformin: clinical topics and new mechanisms of action
Fujita, Y., & Inagaki, N. (2016) · Diabetology International · doi:10.1007/s13340-016-0300-0 · Cited by 14 · see citing works
Neutel, J. M., Zhao, C. Y., & Karyekar, C. S. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0028-9 · Cited by 10 · see citing works
Pala, L., & Rotella, C. M. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0065-x · Cited by 10 · see citing works
Iglay, K., Sawhney, B., Fu, A. Z., Fernandes, G. F., Crutchlow, M. F., Rajpathak, S. N., & Khunti, K. K. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.107 · Cited by 10 · see citing works
Gebregergish, S. B., Hashim, M., Heeg, B. M. S., Wilke, T., Rauland, M., & Gottwald‐Hostalek, U. (2019) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1688146 · Cited by 8 · see citing works
KUMAR, K. M. P., Chawla, M. S., Sanghvi, A., Sastry, N. G., Kotla, C., Phatak, S., & CHOUDHARI, S. Y. (2019) · International Journal of General Medicine · doi:10.2147/ijgm.s179622 · Cited by 8 · see citing works
Juszczyk, E., Kisło, K., Żero, P., Tratkiewicz, E., Wieczorek, M., Paszkowska, J., Banach, G., Staniszewska, M., Hoc, D., Garbacz, G., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060804 · Cited by 6 · see citing works
Stephan, C., & León, W. (2013) · HIV Medicine · doi:10.1111/hiv.12090 · Cited by 5 · see citing works
Chawla, M. S., CHAWLA, P. M., Jethwani, P., Shah, K., & Reddy, S. (2023) · Clinics and Practice · doi:10.3390/clinpract13020045 · Cited by 3 · see citing works
Ghost tablets mimicking intestinal parasite
Lorena Porte, T., & Weitzel, T. (2019) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2019.10.006 · Cited by 2 · see citing works
Comparison of conventional and sustained-release formulation of metformin in type 2 diabetics
Ghorpade, V. V., Hiray, R. S., Daswani, B., & Ghongane, B. B. (2016) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20160654 · Cited by 2 · see citing works
Hinnen, D. A. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000115 · Cited by 2 · see citing works
Emerging concepts in metformin therapy: Hyperglycaemia and beyond
Fiad, T. M., Hammadi, F. A., Nuaimi, A. A., & Dhuhouri, J. A. (2013) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/1947-489x.210550
Combinación en dosis fijas: una nueva opción terapéutica para la diabetes mellitus tipo 2
Goñi, K. M., & Salazar, J. D. (2012) · Medicina Interna de México
Comment and response to: dapagliflozin – do we need it registered for type 2 diabetes?
Jabbour, S. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.974897
Development of metformin tablet that mimics the circadian variation of glucose levels
Rajab, M. (2013) · Digitalen Hochschulbibliothek Sachsen-Anhalt (Universitäts- und Landesbibliothek Sachsen-Anhalt) · doi:10.25673/903
Althanoon, Z. A. (2013) · Al-Mağallaẗ al-ʻirāqiyyaẗ li-l-ṣaydalaẗ · doi:10.33899/iphr.2013.86553
Levy, J., Cobas, R. A., & Gomes, M. B. (2010) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-2-57
Self-citationMannucci, E., & Scoccimarro, D. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_23
Pelluri, R., Kongara, S., Nagasubramanian, V. R., Mahadevan, S., & Chimakurthy, J. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0218
Perspective Chapter: Metformin Origins, Clinical Trials, and Impact in Pharmacy
Tenpas, A. S., Stout, H. K., & Infante, A. F. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1012525
Boriboonhirunsarn, D., & Sunsaneevithayakul, P. (2025) · JMIR Research Protocols · doi:10.2196/79855
Alshadfan, H., Mirghani, H. O., Alrasheed, T., Alanazi, M. A., & Abdullah, M. N. H. (2025) · Pan African Medical Journal · doi:10.11604/pamj.2025.52.176.49165
Mammarella, A. (2014) · MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche
- Authors
- Levy, J., Cobas, R. A., & Gomes, M. B.
- Affiliations
- Universidade do Estado do Rio de Janeiro (BR)
- Corresponding author
- Levy, Juliana
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2010-03-18
- Volume
- 2
- Issue
- 1
- Pages
- 16-16
- ISSN
- 1758-5996 (ISSN-L)
- PMC
- PMC2847989
- OpenAlex
- W2116059552
- Cited by
- 44
- References
- 35
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 4 · 2018: 3 · 2017: 2 · 2016: 3 · 2014: 3 · 2013: 8 · 2012: 4
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-08-25)
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- extended-release metformin, type 2 diabetes, drug efficacy, tolerability, gastrointestinal adverse effects, patient satisfaction, triglycerides, C-reactive protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
